Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00347204

Recruitment Status : Completed

First Posted : July 4, 2006

Last Update Posted : July 4, 2006

Sponsor:

Collaborator:

Allergan

Information provided by:

Center For Excellence In Eye Care

Study Description

Brief Summary:

To determine the ability of two topical Nonsteroidal Anti-inflammatory drops (Acular LS & Nevanac) to help control pain following Photorefractive Keratectomy (PRK).

Condition or disease	Intervention/treatment	Phase
Myopia Hyperopia	Drug: ketorolac (Acular LS) Drug: Nepafenac (Nevanac)	Phase 4

Detailed Description:

Laser Vision Correction is the most commonly performed elective surgical procedure in the United States. Although Laser-Assisted in-situ Keratomileusis (LASIK) is the more popular technique, a growing number of surgeons have switched to surface ablation techniques, including PRK, LASEK and Epi-LASIK.1 With surface laser procedures, the corneal epithelium is removed by a variety of techniques (laser, manual debridement, diluted alcohol2,3, epi-keatome) prior to laser reshaping of the corneal stroma. Following the procedure, a contact lens is placed on the eye to promote epithelial regeneration. Due to the size of the epithelial defect, it can take between 3 to 6 days for the epithelium to regenerate. During this healing process, patients often complain of moderate to severe ocular pain, and delayed healing may result in an increased risk of infection or corneal haze4.

Over the past decade, a variety of methods have been used to assist with reducing pain following surface laser procedures. Topical Nonsteroidals have been shown in a number of studies to help reduce the degree of pain following PRK. Topical dilute tetracaine has also been shown to assist with the reduction of pain following PRK. Oral pain medications, such as Vioxx, Celebrex, and even Prednisone have been recommended as additional treatment options for pain control.

In October 2005, a new topical nonsteroidal anti-inflammatory drop, Nevanac, was approved by the FDA. Nevanac was approved with a a TID dosing schedule.

Acular LS is the current market leader for topical NSAID eye drops. Acular LS is typically used on a QID dosing schedule.

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	40 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	Double Masked Evaluation of Acular LS Versus Nevanac for Postoperative Pain Control in Eyes Undergoing PRK
Study Start Date :	January 2006
Study Completion Date :	June 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Ketorolac Ketorolac tromethamine Nepafenac

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Prevention of postoperative discomfort on postoperative days 1 to 5 after PRK
Best-corrected Visual acuity at all study visits
Degree of corneal haze at all study visits
Time to epithelial closure in each eye after PRK

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients undergoing PRK for myopia or hyperopia

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00347204

Sponsors and Collaborators

Center For Excellence In Eye Care

Allergan

Investigators


Principal Investigator:	William Trattler, MD	Center For Excellence In Eye Care

More Information


ClinicalTrials.gov Identifier:	NCT00347204 History of Changes
Obsolete Identifiers:	NCT00405028
Other Study ID Numbers:	5225
First Posted:	July 4, 2006 Key Record Dates
Last Update Posted:	July 4, 2006
Last Verified:	June 2006

Keywords provided by Center For Excellence In Eye Care:


PRK laser vision correction surface ablation	pain wound healing corneal haze

Additional relevant MeSH terms:


Hyperopia Refractive Errors Eye Diseases Ketorolac Nepafenac Ketorolac Tromethamine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics	Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

To Top